MacroGenics, which is developing targeted therapeutics for cancer and autoimmune diseases, raised $80 million by offering 5 million shares at $16, as anticipated in the revised terms announced Wednesday morning. The company had originally aimed to sell 4 million shares at a price of $14-$16. MacroGenics plans to list on the NASDAQ under the symbol MGNX. BofA Merrill Lynch and Leerink Swann acted as lead managers on the deal.
